HEALTH OF WOMAN. 2017.2(118):111–117; doi 10.15574/HW.2017.118.111

Веропотвелян П. Н., Цехмистренко И. С., Чуваков А. Н., Пивнев М. С., Пивнева Н. В.
Межобластной центр медицинской генетики и пренатальной диагностики, г. Кривой Рог
Перинатальный центр, г. Киев
Многопрофильный медико-диагностический центр, г. Кривой Рог
КУ «Криворожский городской клинический родильный дом № 1» ДОС»
Центр планирования семьи и репродукции человека, г. Кривой Рог

В статье представлены клинико-эпидемиологические данные о папилломавирусной и герпесвирусной инфекции, в частности, о генитальном герпесе – одной из наиболее распространенных вирусных инфекций.

Ключевые слова: вирус папилломы человека, рак шейки матки, персистенция, реинфекция, вирусоносительство, иммуномодуляторы, герпесвирусная инфекция, генитальный герпес, индукторы интерферона.

Литература:
1. Калугина Л.В. ВПЧ и патология репродуктивной системы / ДУ «Институт педиатрии, акушерства и гинекологии НАМНУ». – К., 2013.

2. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Rceomm. Rep. 2006; 55(RR-11): 62–7.

3. De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer. 2009; 124(7): 1626–36. https://doi.org/10.1002/ijc.24116

4. Russomano F., Reis A., de Camargo M.J., Dutra M.V., Fonseca S.C., Anderson J. Efficacy in treatment of subclinical cervical HPV infection without intraepithelial neoplasia: systematic review. San Paulo Med. J. 2000; 118(4): 109–15. https://doi.org/10.1590/S1516-31802000000400007; PMid:10887387

5. Smith M.A., Canfell K., Brotherton J.M.L., Lew J.-B., Barnabas R.V. The predicted impact of vaccination on human papillomavirus infections in Australia. Int. J. Cancer. 2008; 123(8): 1854–63. https://doi.org/10.1002/ijc.23633; PMid:18636563

6. Lobato S., Tafuri A., Fernandes P.A., Caliari М.V., Silva M.X., Xavier M.A., Vago A.R. Minichromosome maintenance 7 protein is a reliable biological marker for human cervical progressive disease. J. Gynecol. Oncol. 2012; 23(1): 11–5.

7. Garland S.М., Insinga R.P., Sings H.L., Haupt R.M., Joura E.A. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol. Biomarkers Prev. 2009; 18(6): 1777–84. https://doi.org/10.1158/1055-9965.EPI-09-0067; PMid:19505910

8. Brown C.A., Bogers J., Sahebali S., Depuydt C.E., De Prim F., Malinowski D.P. Role of protein biomarkers in the detection of high– grade disease in cervical cancer screening programs. J. Oncol. 2012; 2012: 289315. https://doi.org/10.1155/2012/289315; PMid:22481919 PMCid:PMC3317214

9. Batkaev E.A. Genital herpes. Journal of Postgraduate Medical Education. 2013; 3: 20–3.

10. Levin A.E., Samoutine F.L. Neovir monotherapy in chronic recurrent genital herpes. Diseases transmitted through sexual contact. 1998; 1: 18–21.

11. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol. Rec. 2014; 89(21): 221–36.

12. Prilepskaya V.N., Nazarova N.M., Mzarelua G.M., Fazullin L.Z., Trofimov D.Yu. HPV-associated cervical disease – new in diagnostics // Obstetrics and Gynecology 2015; 9: 20–26.

13. Workowski K.A., Berman S.; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm. Rep. 2010; 59(RR-12): 1–110.

14. Zhao Y, Cao X, Zheng Y. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2. J Med Virol. 2012;4:12: 1920–1927. https://doi.org/10.1002/jmv.23353; PMid:23080497

15. Brown D.R., Shew M.L., Oadadri B., Neptune N., Vargas М., Tu W. et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis. 2005; 191(2): 182–92.

16. Tornesello M.L., Duraturo M.L., Losito S., Botti G., Pilotti S., Stefanon B. et al. Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int. J. Cancer. 2008: 122(1): 132–7.

17. Robinson D., Coupland V, Mailer H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br. J. Canccr. 2009; 100(3): 527–31. https://doi.org/10.1038/sj.bjc.6604871

18. Shukla S., Bharti A.C., Mahata S., Hussain S., Kumar R., Hedau S., Das B.C. Infection of human papillomaviruses in cancers of different human organ sites. Indian J. Med. Res. 2009; 130(3): 222–33.

19. Grm H.S., Bergant M., Banks L. Human papillomavirus infection, cancer and therapy. Indian J. Med. Res. 2009; 130(3): 277–85.

20. Hsueh P.R. Human papillomavirus, genital warts, and vaccines. J. Microbiol. Immunol. Infect. 2009; 42(2): 101–6.

21. Palefsky J.M., Cranston R.D., Dezube B.J., Ross M.E. Anal intraepithelial neoplasia: diagnosis, screening, prevention, and treatment. 2012. Ct. opubl. na UpToDate onlajn (konsul’tativnyj med. forum v SShA).

22. Schiffman М., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370(9590): 890–907.

23. Dyson S., Pitts М., Lyons A., Mullins R. Providing high quality information about human papillomavirus for women after treatment for high-grade cervical dysplasia. Sex. Health. 2010; 7(1): 49–54.

24. Pepas L., Kaushik S., Bryant A., Nordin A., Dickinson H.О. Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst. Rev. 2011; (4).

25. Wang H.K., Duffy A.A., Broker T.R., Chow L.T. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 2009; 23(2): 181–94. https://doi.org/10.1101/gad.1735109; PMid:19131434 PMCid:PMC2648537

26. Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M. et al.; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol. 2013; 121(4): 829–46.

27. Wang X., Wang H.-K., Li Y. microRNAs are biomarkers of oncogenic human papillomavirus infections. Proc. Natl. Acad. Sci. USA. 2014; 111(11): 4262–7.

28. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63(6): 1129–36. https://doi.org/10.1016/0092-8674(90)90409-8

29. Roman A., Munger K. The papillomavirus E7 proteins. Virology. 2013;445(1-2): 138–68.

30. Hryanin A.A., Reshetnikov O.V. Inductors interferon in the treatment of genital herpes in women // Obstetrics and Gynecology 2015; 7: 88–89.

31. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004; 11(Suppl. 1): 24A–35A.

32. Nandakumar S., Woolard S.N., Yuan D., Rouse B.T., Kumaraguru U. Natural killer cells as novel helpers in anti-herpes simplex virus immune response. Journal of virology. 2008 Nov; 82(21).

33. Dovlethanova E.R., Prilepskaya V.N. A differentiated approach to the treatment of genital disease in women associated with HPV infection // Obstetrics and Gynecology 2015; 10: 118–124.

34. Rogovskaya N.Y., Bebneva T.N., Nekrasov P.I., Polonskaya N.Y. Efficiency of treatment of diseases of the genitals with a combination of human papillomavirus and herpes virus infection // Obstetrics and Gynecology 2014; 9: 90–97.

35. Beauman J.G. Genital herpes: a review. Am. Fam. Physician. 2005; 72(8):1527–34.

36. Bauer G. The color atlas on кольпоскопии / the Lane with him. O.A. Zubanova; under the editorship of S.I. Rogovskaya. – M.: GEOTAR – HONEY 2002.

37. Danilov E.V. Influence of a human papillomavirus infection on the course of pregnancy. «EFFECTIVE PHARMACOTHERAPY. Obstetrics and gynecology. Special issue (38), 2014.

38. Protasova A.E., Dzyuby T.I., Raskin G.A., Tapilskaya N.I., Zazerskaya I.E., Hadzhiyeva E.D. Displaziya of a uterus neck – этиопатогенез, diagnostics, optimum tactics of treatment. Manual. – SPb.: 2014; 22 p.